Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of α-SMA and NF-κB

Lung myofibroblasts play a major role in the pathophysiology of asthma, contributing not only to tissue remodelling but also to airway inflammation. Nevertheless, only recently, attention has been focused on these cells as potential targets for anti-allergic drugs. Herein, we analysed the pharmacolo...

Full description

Saved in:
Bibliographic Details
Published in:International immunology 2005-11, Vol.17 (11), p.1473-1481
Main Authors: Baouz, Soria, Giron-Michel, Julien, Azzarone, Bruno, Giuliani, Massimo, Cagnoni, Francesca, Olsson, Susanna, Testi, Renato, Gabbiani, Giulio, Canonica, G. Walter
Format: Article
Language:English
Subjects:
airway inflammation
airway remodelling
asthma
FP    fluticasone propionate
NF-κB    nuclear factor-κB
p.d.l.    population doubling level
RT    reverse transcription
r    recombinant
SMC    smooth muscle cell
SMl    salmeterol
TGF    transforming growth factor
TNF-α    tumour necrosis factor-α
α-SMA    α-smooth muscle actin
β2-agonists
β2-AR    β2-adrenergic receptor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung myofibroblasts play a major role in the pathophysiology of asthma, contributing not only to tissue remodelling but also to airway inflammation. Nevertheless, only recently, attention has been focused on these cells as potential targets for anti-allergic drugs. Herein, we analysed the pharmacological response of lung myofibroblasts to β2-agonists associated or not to inhaled corticosteroids, investigating their effects on (i) the constitutive and transforming growth factor-β (TGF-β)-induced expression of α-smooth muscle actin (α-SMA), the main functional marker of myofibroblastic differentiation and contractility; (ii) isometric contraction and (iii) tumour necrosis factor-α (TNF-α)-induced nuclear translocation of the pro-inflammatory transcription factor nuclear factor-κB (NF-κB). The β2-agonist salmeterol (SMl) has on human lung myofibroblasts new direct anti-contractile/anti-inflammatory effects that are amplified by the combined use of low concentrations of the glucocorticoid fluticasone propionate (FP). First, SMl and/or FP (10−12 M) inhibits the constitutive and TGF-β-induced expression of α-SMA. Second, the two drugs block the TNF-α-induced nuclear translocation of the pro-inflammatory transcription factor NF-κB. Finally, SMl decreases TNF- α-induced production of the inflammatory cytokine IL-6. The complementary anti-inflammatory/ anti-contractile effects displayed by SMl and FP on lung myofibroblasts in vitro may be related to the improvement in lung function and symptom control obtained in vivo by the early use of low doses of glucocorticoids in combination with long-acting β2-agonists.
ISSN:0953-8178
1460-2377
DOI:10.1093/intimm/dxh325